Skip to main content

Advertisement

SpringerLink
Log in

International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ADCC:

Antibody-dependent cell-mediated cytotoxicity

BCMA:

Bispecific B-cell maturation antigen

CDK:

Cyclin-dependent kinase

cHL:

Classical Hodgkin’s lymphoma

CLDN:

Claudin

MEK:

Mitogen-activated kinase kinase

MSI-H:

Microsatellite instability high

Smac:

Second mitochondria-derived activator of caspase

STING:

Stimulator of interferon genes protein

TIGIT:

T cell immunoreceptor with Ig and ITIM domains

TRAF:

TNF receptor associated factor

Trex:

Three prime repair exonuclease

T-vec:

Talimogene laherparepvec

Acknowledgements

We are grateful to Belen Palencia, Esther Guirado and Cibeles Pinto for excellent meeting logistics.

Funding

The meeting was supported by the Ramón Areces foundation, Center for Applied Medical Research (CIMA), Clínica Universidad de Navarra, GETICA, GEIT, REINCA, IDISNA, ADITECH and the following pharmaceutical companies: AstraZeneca, Takeda, Lilly, Merck, Merck Sharp & Dohme Corp (MSD), Roche, Bristol-Myers Squibb and Boehringer-Ingelheim.

Author information

Authors and Affiliations

  1. Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Edificio CIMA, Avenida Pio XII 55, 31008, Pamplona, Spain

    Pedro Berraondo, Maria Angela Aznar, Elisabeth Perez-Ruiz, Maria Esperanza Rodriguez-Ruiz & Ignacio Melero

  2. Navarra Institute for Health Research (IDISNA), Pamplona, Spain

    Pedro Berraondo, Maria Esperanza Rodriguez-Ruiz, Jose Luis Perez-Gracia & Ignacio Melero

  3. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain

    Pedro Berraondo, Maria Esperanza Rodriguez-Ruiz, Jose Luis Perez-Gracia & Ignacio Melero

  4. Division of Medical Oncology, Hospital Costa del Sol, Marbella, Spain

    Elisabeth Perez-Ruiz

  5. Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

    Eduardo Castañon, Jose Luis Perez-Gracia & Ignacio Melero

Authors
  1. Pedro Berraondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Angela Aznar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabeth Perez-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Esperanza Rodriguez-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardo Castañon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jose Luis Perez-Gracia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ignacio Melero
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors made notes at the symposium which served as the basis for this meeting report. PB and IM wrote the manuscript, and all authors completed and approved the final version.

Corresponding authors

Correspondence to Pedro Berraondo or Ignacio Melero.

Ethics declarations

Conflict of interest

Ignacio Melero is a consultant for Bristol-Myers Squibb, Roche-Genentech, Medimmune, Merck Serono, Bioncotech, F-STAR, Genemab and Tusk. He receives grants from Bristol-Myers Squibb, Roche-Genentech and Alligator. Jose Luis Perez-Gracia is an advisor to Bristol Myers and Roche-Genentech. The rest of the authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berraondo, P., Aznar, M.A., Perez-Ruiz, E. et al. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain. Cancer Immunol Immunother 67, 1809–1813 (2018). https://doi.org/10.1007/s00262-018-2240-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-018-2240-y

Keywords

Search

Navigation